Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 7/20 | 0.62 |
| ▸ | CDK2 | P24941 | 8/20 | 0.49 |
| ▸ | CDK4 | P11802 | 4/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.44 |
| ▸ | CDK9 | P50750 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521750 | 0.89 | IKBKB (0.65) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL4880084 | 0.88 | IKBKB (0.63) | IKBKBCDK2CDK4CDK1CCNT1 | |
| Acetic Acid SCHEMBL4877880 | 0.86 | IKBKB (0.60) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3516494 | 0.85 | IKBKB (0.70) | IKBKBCDK2CDK4CDK1ALDH1A1 | |
| Acetic Acid SCHEMBL4877291 | 0.84 | IKBKB (0.59) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3520096 | 0.84 | IKBKB (0.49) | IKBKBCDK2 | |
| SCHEMBL3515574 | 0.84 | IKBKB (0.64) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3522199 | 0.83 | IKBKB (0.65) | IKBKBCDK2CDK4CDK1CCNT1 | |
| SCHEMBL3517601 | 0.82 | IKBKB (0.73) | IKBKBCDK2CDK4CDK1HDAC4 | |
| SCHEMBL3519740 | 0.81 | IKBKB (0.75) | IKBKBCDK2CDK4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | GALE, UGGT1, UGT1A3 | IKBKB 4349/4885CDK2 660/4885CDK4 514/4885 |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | CSNK1A1, PRKX, PRKACA | IKBKB 327/4885CDK2 123/4885CDK4 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.